Onconetix Registers 100M Shares for Resale, Potential 2,532% Dilution
ONCO sits 37% above its 52-week low of $0.665 on light trading volume (0.2× avg).
Summary
Onconetix filed an S-1 to register 100 million shares for resale by Seven Knots LLC, representing potential dilution of 2,532% if fully converted. The shares are issuable upon conversion of Series F Preferred Stock from the July 2026 PIPE, with an initial conversion price of $0.9767.
Key Events · Financing and Capital Events · ONCO
-
100M Share Resale Registration
Registers 100,000,000 shares for resale by Seven Knots LLC upon conversion of Series F Preferred Stock from the July 2026 PIPE.
-
Massive Potential Dilution
If all 100M shares were issued, dilution would be 2,532% of the 3,949,107 shares outstanding as of August 10, 2026.
-
Conversion Price Set at $0.9767
Series F Preferred Stock converts at an initial price of $0.9767 per share, subject to adjustment.
-
Nasdaq Exchange Cap Limits Issuance
Until stockholder approval, only 789,426 shares can be issued due to Nasdaq's 19.99% Exchange Cap.
Analysis · ONCO · Life Sciences
This S-1 registers 100 million shares for resale by Seven Knots LLC upon conversion of Series F Preferred Stock issued in the July 2026 PIPE. The initial conversion price is $0.9767, and if all registered shares were issued, dilution would be 2,532% of the current 3.95 million shares outstanding. However, Nasdaq's Exchange Cap currently limits issuance to 789,426 shares until stockholder approval is obtained. The company has a going concern warning and only $5.4 million in cash as of August 10, 2026, making this registration a critical step in accessing capital but also a massive overhang on the stock.
At the time of this filing, ONCO was trading at $0.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.67 to $209.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.